The goal of this research project is to better understand the functions of Myt1l during normal embryonic brain development. As part of their genetic approach, Marius Wernig and Thomas Südhof will primarily focus on heterozygous mutant cells since the heterozygote condition is more similar to what is found in individuals with autism.

Individuals with autism frequently experience visceral pain, constipation and diarrhea, but the mechanisms underlying such gastrointestinal symptoms are poorly understood. In the current project, David Julius’ laboratory is focused on delineating the properties of enterochromaffin cells, the serotonin-producing epithelial cells of the gut that detect noxious agents, communicate with sensory nerve fibers and contribute to visceral pain

By integrating in vitro, ex vivo and in vivo techniques, Ori-McKenney will provide insight into how MNB/DYRK1a contributes to autism.

This project aims to develop computational technologies to model human protein-protein interaction networks that are perturbed in autism.

This project aims to study pharmacological tools that enhance energy production efficiency in neurons as a way to enhance learning and memory in individuals with fragile X syndrome.

Crabtree and Gleeson will focus on rare high-impact genetic mutations for factors in the BAF complex to test how links between neuronal activity and the epigenome may be interrupted in ASD.